11 results about "Serum specimen" patented technology

The invention relates to the technical field of serum specimen typing identification, in particular to a serum specimen typing identification system based on patient centralized detection. Comprising a data acquisition module, a data processing module, a data analysis module and a typing identification module, the data acquisition module is used for collecting and recording serum index data of a patient; according to the method, serum index data, including C-reactive protein, glucose, lactic dehydrogenase, TNF-alpha, IgG and IgM, of the patient are collected, an index matrix is constructed, and homogenization treatment is performed, so that a serum index distribution map of the patient is formed, the relationship between serum index values of the patient is conveniently and intuitively reflected, the synergistic reaction effect of each index on inflammation is reflected, and the sensitivity of the patient is improved. Meanwhile, a serum specimen of a new patient is subjected to typing, disease indexes are calculated, and medical staff can conveniently carry out targeted treatment on the patient.

The invention discloses a coater for clinical treponema pallidum non-specific antibody detection test. The coater comprises a main body hollow handle, a rubber coating sleeve and a standby liquid injector, wherein the main body hollow handle comprises a handle body, a handle piston rod, a liquid injection port and a main body needle head; the rubber smearing sleeve is integrally formed and comprises an outer wrapping connector and a smearing wafer. And the liquid injection part comprises an independent standby injector. The coater can store liquid, is large and uniform in coating surface and convenient to operate, the liquid outlet amount is convenient to adjust due to piston type liquid outlet, the needle head, the coating wafer and the like can be replaced, the problem of coating a serum specimen is effectively solved, and the coater is used for coating a treponema pallidum non-specific antibody detection test specimen.

The present application relates to a specimen extraction solution and a specimen extraction method, and an inspection reagent using the same, the specimen extraction solution containing a component capable of inhibiting false negative reactions that cannot be completely inhibited by conventional methods when detecting antigens such as viruses, bacteria, and proteins to be detected from specimens from body fluids such as a nasal swab specimen, a nasal aspirate specimen, a nasal lavage specimen, a nasal discharge specimen, a throat swab specimen, a saliva specimen, a fecal specimen, a serum specimen, a plasma specimen, a urine specimen, and the like using an inspection reagent that utilizes antigen-antibody reactions or reactions of substances having interactions with each other. The specimen extraction solution of the inspection reagent, or a component that comes into contact with a specimen in a process before a detection reaction of a detection object or a process performed simultaneously with the detection reaction, and the like contain a water-soluble compound having a phenyl group, a benzyl group, a tolyl group, or a xylyl group in the structure, and at least a functional group including a carboxyl group or a carboxyl group methylated or ethylated atom group or a hydroxyl group bonded to the above group.

The invention relates to the technical field of lung cancer, in particular to a method for predicting EGFR gene mutation in non-small cell lung cancer based on an endogenous formaldehyde and serum tumor marker combined kit. Comprising the following steps: 1, detecting the concentration of endogenous formaldehyde FA in a serum sample; 2, detecting the concentration of tumor markers in the serum specimen by using a chemiluminescence method, wherein the tumor markers comprise squamous cell carcinoma antigen SCC-Ag and carcino-embryonic antigen CEA; and 3, inputting the concentrations of endogenous formaldehyde FA, a serum tumor marker CEA and a squamous epithelial cell carcinoma antigen SCC-Ag by adopting IBM SPSS 27.0 statistical software, drawing an ROC curve for diagnosing the EGFR mutation state, and predicting EGFR gene mutation according to the ROC curve. According to the invention, the prediction of the accuracy of the next-generation sequencing result by serology is realized through a CEA + SSCC-Ag + FA triple method, tests show that the AUC of the CEA + SSCC-Ag + FA triple method reaches 0.77, the P value is 0.001, the prediction accuracy is the highest, and a basis is further provided for EGFR gene detection of lung adenocarcinoma patients.

The invention discloses a novel substrate of PCSK7 hydrolase and application of the novel substrate in detection of iron overload related diseases. The invention finds that IGF2R may be a new hydrolysis substrate of PCSK7 hydrolase, and IGF2R expression increase caused by IGF2R hydrolysis reduction caused by PCSK7 mutation of a hereditary hemochromic disease patient may be related to the attack of the hereditary hemochromic disease. In particular, the PCSK7 can be used for specifically hydrolyzing the extracellular part of the IGF2R, so that soluble IGF2R (sIGF2R) is formed and can be detected in serum. Therefore, the IGF2R can be used as a molecular marker for detecting and treating iron overload related diseases such as hemochromia, and can be used for detecting sIGF2R in serum of patients with the iron overload related diseases by preparing a clinical diagnostic kit. The kit comprises a solid-phase carrier, an IGF2R antibody coated on the solid-phase carrier, an enzyme-labeled secondary antibody, a standard substance, a chromogenic substrate, a washing solution and a reaction stop solution. The detection kit can be used for specifically and quantitatively detecting the level of sIGF2R in a serum specimen.

The utility model discloses a subpackage freezing storage device for serum specimens, which relates to the technical field of medical equipment and comprises a subpackage tube, a subpackage seat and a thawing extrusion seat, the subpackage tube is of a square column-shaped structure with square ribs fixedly connected to the centers of two sides, a round through hole is formed in the center of the subpackage tube, and the round through hole is communicated with the subpackage seat. The bottom of a round through hole of the split charging pipe is fixedly connected with a split charging needle-threading rubber plug, the split charging pipe can be used for split charging and storing blood samples, the split charging seat can be matched with the split charging pipe through the split charging seat, uniform split charging of the serum samples is achieved, whole freezing storage is achieved, only the split charging seat needs to be labeled, distinguishing and finding are convenient, and the split charging efficiency is improved. By means of the arranged thawing extrusion base, the thawing extrusion base can be matched with the split charging pipe, thawing of serum can be accelerated, transfer and detection of the serum can be achieved without transferring the serum to a PCR pipe, multiple sets of operation can be conducted at the same time, and the operation steps of serum sample detection are greatly reduced.

The invention relates to the technical field of blood glucose measurement, in particular to a method for measuring serum glucose concentration. The method comprises the following steps: firstly, respectively preparing a glucose oxidase solution, a glucose standard solution, a ferrous sulfate solution, a potassium thiocyanate solution and a sulfuric acid solution, then adding a collected serum specimen and the glucose oxidase solution into a colorimetric tube for incubation, and then adding the ferrous sulfate solution and the sulfuric acid solution for further reaction; and finally, adding a potassium thiocyanate solution to fully react, and measuring the absorbance A so as to calculate the concentration of glucose in the serum. The method is simple in operation process and low in cost, and used reagents are safe, harmless and long in storage time; the light sensitivity is good, the lowest detection limit is 0.008 mmol / L, and the clinical blood glucose detection requirement is met; the method is good in repeatability and strong in anti-interference capability, the determination wavelength is 460nm, the influence of the natural color of serum is avoided, and the interference caused by coexisting substances is effectively overcome by taking enzyme blank as a contrast.

The present invention discloses a kit for quantitatively detecting serum autoantibodies in gastric cancer and precancerous lesions and its application. The kit includes a solid-phase carrier, a recombinant antigen protein coated on the solid-phase carrier, an enzyme-labeled secondary antibody, a standard product, a chromogenic substrate, a washing solution, and a reaction termination solution. This detection kit can specifically and quantitatively detect the levels of RAE1, PGK1, and NPM1 autoantibodies in serum specimens, and is significantly superior to the currently clinically used serum markers CEA and CA19-9 in terms of sensitivity for early screening and diagnosis of gastric cancer and precancerous lesions.

The present invention belongs to the field of biomedicine technology, discloses the application of TFF1 and TFF3 in the early diagnosis of lung cancer bone metastasis, and specifically discloses the application of a substance for detecting biomarkers in the preparation of a product for diagnosis or early screening of lung cancer bone metastasis; the biomarkers include TFF1 and / or TFF3. The present invention discloses for the first time the relationship between the expression of secretory proteins TFF1 and TFF3 and specific bone metastasis of lung cancer, and verifies that secretory proteins TFF1 and TFF3 are specifically highly expressed in serum specimens of patients with lung cancer bone metastasis and lung cancer bone metastasis cells, suggesting that secretory proteins TFF1 and TFF3 can be used as a new diagnostic marker for lung cancer bone metastasis, which can significantly distinguish lung cancer patients with bone metastasis from lung cancer patients with metastasis to other organs and healthy people.

The application provides an automatic reading method and system for antibody identification results based on a vector space model, which comprises the following steps: constructing an antibody specificity vector model, mapping the antigen spectrum corresponding to each antibody specificity in an antibody identification pedigree table into an antibody specificity vector with a fixed dimension; mapping the reaction results of antibody identification of a serum sample to be tested into a to-be-tested vector through the antibody specificity vector model; calculating the similarity between the to-be-tested vector and the antibody specificity vector; and performing reading based on reading logic according to the similarity calculation results to obtain antibody identification results. The antibody identification results can be automatically read by calculating the vector similarity, the antibody identification can be realized quickly, accurately and standardly, and the work efficiency is improved significantly, and the manpower is liberated.

The application belongs to the technical field of biological medicine, discloses application of bone metastasis specific secreted protein DKK3 in early diagnosis of lung cancer bone metastasis, and specifically discloses application of a substance for detecting DKK3 in preparation of a product for diagnosing or early screening of lung cancer bone metastasis. The application discloses the relationship between secreted protein DKK3 expression and lung cancer specific bone metastasis for the first time, and verifies that secreted protein DKK3 is specifically highly expressed in serum samples of lung cancer bone metastasis patients and lung cancer bone metastasis cells, which indicates that secreted protein DKK3 can be used as a new lung cancer bone metastasis diagnostic marker, and can significantly distinguish lung cancer patients with bone metastasis from lung cancer patients with metastasis to other organs and healthy people.